Forbes June 16, 2022
Bruce Japsen

Walgreens is launching a clinical trial business, hoping to increase racial and ethnic diversity for patients in drug research.

Walgreens effort in clinical trials comes as the U.S. Food and Drug Administration and the Biden White House look to improve drug research and patient health outcomes by enrolling more Americans from underrepresented racial and ethnic populations into U.S. clinical trials.

The FDA has acknowledged that racial and ethnic minorities are “frequently underrepresented in biomedical research,” the agency said two months ago when outlining the government’s steps to improve diversity in clinical trials given an estimated one in five drugs have varied responses in ethnic groups yet most clinical trial participants are white.

For its part, Walgreens said it will be...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Clinical Trials, FDA, Govt Agencies, Pharma, Pharma / Biotech, Trends
Challenges in Trial Access and Treatment for Women with Chronic Illnesses
Brainomix AI shows its worth in AZ pulmonary fibrosis trial
Moderna moves three vaccines into final stage trials as it works to rebound from Covid slump
'From Interpretation to Action': Using CGM to Manage T2D
Oncology in 2024: The clinical trial trends reshaping the role of CROs

Share This Article